Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.49 |
| ▸ | RXRG | P48443 | 16/20 | 0.49 |
| ▸ | RXRB | P28702 | 14/20 | 0.49 |
| ▸ | RARG | P13631 | 7/20 | 0.48 |
| ▸ | RARB | P10826 | 7/20 | 0.46 |
| ▸ | RARA | P10276 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920534 | 1.00 | RXRA (0.49) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL8308616 | 0.93 | RXRA (0.48) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL8308614 | 0.93 | RXRA (0.48) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL4970582 | 0.81 | RXRA (0.48) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL4970588 | 0.81 | RXRA (0.48) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6037060 | 0.80 | RXRA (0.53) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6037059 | 0.80 | RXRA (0.53) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6037058 | 0.76 | RXRA (0.52) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL7914094 | 0.76 | RXRA (0.52) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL8806906 | 0.71 | RXRA (0.34) | RXRARXRGRXRBRARGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | claimed |
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | disclosed |
| EP-1143953-A3 | METHOD OF INHIBITING ANGIOGENESIS | Genentech, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-1143953-A2 | METHOD OF INHIBITING ANGIOGENESIS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000030628-A2 | METHOD OF INHIBITING ANGIOGENESIS | GENENTECH, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RXRA 6/4885RXRG 3/4885RXRB 5/4885 |
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RXRA 6/4885RXRG 3/4885RXRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.